Eli Lilly and Company (NYSE: LLY) is a prominent player in the pharmaceutical industry, known for its innovative drug development and healthcare solutions. On March 10, 2026, Bernstein reiterated its "Outperform" rating for LLY, with the stock priced at $1,008.39. This rating suggests confidence in the company's future performance and potential for growth.
The Bank of Montreal Can has shown increased confidence in Eli Lilly by boosting its stake by 8.9% during the third quarter. The bank now holds 1,569,917 shares, having acquired an additional 127,679 shares. This investment is valued at $1.2 billion, representing approximately 0.17% of Eli Lilly's total shares.
Other institutional investors have also adjusted their positions in Eli Lilly. Brighton Jones LLC increased its holdings by 22% in the fourth quarter, now owning 9,597 shares valued at $7.4 million. Revolve Wealth Partners LLC raised its holdings by 2.8%, now possessing 1,471 shares, indicating a broader trend of investor confidence in the company.
The stock for LLY is currently priced at $1,008.39, reflecting an increase of 1.82% or $18.06. During the day, the stock fluctuated between a low of $980.58 and a high of $1,008.86. Over the past year, LLY has reached a high of $1,133.95 and a low of $623.78, showcasing its volatility and potential for growth.
Eli Lilly's market capitalization stands at approximately $951.27 billion, highlighting its significant presence in the pharmaceutical sector. The trading volume for LLY is 2,016,365 shares on the NYSE, indicating active investor interest and engagement with the stock.
